The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Macular Edema

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

At baseline, the macular thicknesses of both eyes of the patients with persistant diabetic macular edema were measured by optical coherence tomography. After 3.75mg bevacizumab was injected into subconjunctival space of the eyes with diabetic macular edema. The measurements of the macular thicknesses were repeated by optical coherence tomography in 15th, 30th, 60th day after injections. The macular thickness measurements before and after injection were compared.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Having diffuse diabetic macular edema persisted at least 1 month
No intravitreal injection in last 3 months.
No retinal laser photocoagulation in last 6 months
Not have any other macular disease causing macular edema

Exclusion criteria

Having ischemic macula
Intravitreal injection in last 3 months.
Retinal laser photocoagulation in last 6 months
Have any other macular disease causing macular edema

Treatment and study plan

Subconjunctival bevacizumab (Altuzan)

Drug

Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.

Primary outcomes

Central Macular Thickness

Time frame: one year (between May 2015 and May 2016)

Sponsors and collaborators

Lead sponsor

Neon Hospital

Other

Collaborators

Ondokuz Mayıs University

Registry information

Important dates

Study start: 2015
Primary completion: 2016
Study completion: 2016
First posted: Jun 10, 2016
Registry last updated: Jun 10, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed